Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Assets (2016 - 2026)

Aytu Biopharma has reported Current Assets over the past 15 years, most recently at $76.2 million for Q4 2025.

  • Quarterly Current Assets rose 20.92% to $76.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $79.2 million for FY2025, 27.93% up from the prior year.
  • Current Assets was $76.2 million for Q4 2025 at Aytu Biopharma, down from $81.1 million in the prior quarter.
  • Over five years, Current Assets peaked at $105.2 million in Q2 2021 and troughed at $59.9 million in Q2 2022.
  • The 5-year median for Current Assets is $72.8 million (2023), against an average of $74.9 million.
  • Year-over-year, Current Assets skyrocketed 39.53% in 2021 and then crashed 43.05% in 2022.
  • A 5-year view of Current Assets shows it stood at $87.5 million in 2021, then fell by 19.34% to $70.6 million in 2022, then rose by 1.08% to $71.4 million in 2023, then decreased by 11.65% to $63.1 million in 2024, then increased by 20.92% to $76.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Current Assets are $76.2 million (Q4 2025), $81.1 million (Q3 2025), and $79.2 million (Q2 2025).